Skip to Main Content

Author Details

Robert E Reiter
David Geffen School of Medicine at university of california los angeles
1993
229
60
PMIDPaper TitleJournal TitlePublished Year
35058580Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT.Prostate Cancer Prostatic Dis2023
37482512Presurgical <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.Eur Urol2023
37639648Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.J Clin Oncol2023
37060201A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.Cancer2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
36723856Multimodality Therapies for Localized Prostate Cancer.Curr Oncol Rep2023
36935345Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).Eur Urol2023
36870853Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.Eur Urol Oncol2023
36824946Racial Disparities in Quantitative MRI for African American and White Men with Prostate Cancer.Res Sq2023
36797449LUNAR: a randomized Phase 2 study of <sup>177</sup> Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).BJU Int2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
36863416Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials.Int J Radiat Oncol Biol Phys2023
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
36269935Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.J Clin Oncol2023
36007724Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.Int J Radiat Oncol Biol Phys2023
32958451Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.Eur Urol Oncol2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
35505417Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena.J Hematol Oncol2022
35469702High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.Eur Urol2022
35450732Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.Eur Urol2022
35848770Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial.J Urol2022
36509074NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.J Natl Compr Canc Netw2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
35869359Dictionary learning compressed sensing reconstruction: pilot validation of accelerated echo planar J-resolved spectroscopic imaging in prostate cancer.MAGMA2022
35934601Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).Eur Urol2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
33602654Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.Eur Urol Oncol2022
34860274The utility of prostate MRI within active surveillance: description of the evidence.World J Urol2022
34854746Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.J Urol2022
35051385Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.Lancet Oncol2022
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
34400799Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials.Prostate Cancer Prostatic Dis2022
34649942Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial.J Nucl Med2022
31411981Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.Eur Urol Oncol2021
33908801Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.J Urol2021
33545689NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.J Natl Compr Canc Netw2021
33876838Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.Prostate2021
33542230Prostate cancer.Nat Rev Dis Primers2021
33541838The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer.Eur Urol Focus2021
33647456Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.Mol Ther2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
34591333Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.Prostate2021
34529005Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.JAMA Oncol2021
34554200Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.JAMA Oncol2021
34679484Textured-Based Deep Learning in Prostate Cancer Classification with 3T Multiparametric MRI: Comparison with PI-RADS-Based Classification.Diagnostics (Basel)2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
33309278A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).Eur Urol2021
33219015High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.Clin Cancer Res2021
  • 1 - 50 of 229

Recommended Authors

Simpa S Salami
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 53
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Career Start Year 2008
Number of shared co-authors 42
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 16
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 32
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 18
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 40
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 29
Mathieu Latour
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2001
Number of shared co-authors 16
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 30
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 12
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 13
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 19
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 21
Todd M Morgan
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 91
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 19
Andrew J Evans
Princess Margaret Cancer Center, University Health Network.
Career Start Year 1996
Number of shared co-authors 13
Alan Thompson
The Royal Marsden NHS Foundation Trust
Career Start Year 1996
Number of shared co-authors 10
Lars Egevad
Karolinska Institute
Career Start Year 1995
Number of shared co-authors 28
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 43
Alexandre R Zlotta
University Health Network, Princess Margaret Cancer Center, University of Toronto
Career Start Year 1993
Number of shared co-authors 15
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 29
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 42
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 9
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 56
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 57
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 35
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 51
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 15
Dominique Trudel
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 18
John Trachtenberg
University of Toronto, University Health Network
Career Start Year 1971
Number of shared co-authors 12

Collaborators

Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 49
Steven S Raman
University of California, Los Angeles David Geffen School of Medicine
Co-authored papers 42
Amar U Kishan
University of California los angeles
Co-authored papers 38
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 35
Michael L Steinberg
University of California los angeles
Co-authored papers 34
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 34
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 31
Daniel J Margolis
Weill Cornell Medical College
Co-authored papers 30
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 30
Jeremie Calais
university of california los angeles
Co-authored papers 22
Anthony Sisk
University of California los angeles
Co-authored papers 20
Eric J Small
University of California san francisco
Co-authored papers 19
Owen N Witte
University of California los angeles
Co-authored papers 19
Martin E Gleave
University of British Columbia
Co-authored papers 19
Christopher R King
University of California los angeles
Co-authored papers 18
Christopher P Evans
University of California Davis
Co-authored papers 18
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 17
Johannes Czernin
university of california los angeles
Co-authored papers 17
David Elashoff
David Geffen School of Medicine at University of California los angeles
Co-authored papers 17
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 15
Kim N Chi
University of British Columbia
Co-authored papers 14
Ely R Felker
University of California, Los Angeles David Geffen School of Medicine
Co-authored papers 13
Adam Foye
University of California San Francisco
Co-authored papers 13
Rahul Aggarwal
University of California San Francisco
Co-authored papers 13
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 13
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 13
Ting Martin Ma
University of Washington
Co-authored papers 13
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 13
Thomas J George
UF Health Cancer Center
Co-authored papers 11
Paul C Boutros
University of California los angeles
Co-authored papers 11
Release 1.2